Zepbound week 6 update: what the science says about early results

What did @dysfunctionaldej actually say?

At week 6 on Zepbound (tirzepatide), this creator reports losing 17 pounds total, including 3 pounds in the past week, while staying on the starting dose of 2.5 mg. She's 5'2", started at 180 pounds, and pays $277 for the medication. She plans to stay on 2.5 mg for a full two months before titrating up, citing continued loss as her reason to wait. She also added gym sessions this week, specifically because she was worried about losing muscle mass, and experienced what she believes was food poisoning, not a medication side effect.

That's actually a lot of medically relevant detail packed into one TikTok. The dose, the titration logic, the muscle concern, the hydration push. She's not just posting transformation content. She's tracking this seriously.

Does the science back this up?

Mostly, yes. Tirzepatide's phase 3 SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed participants losing an average of 20.9% body weight over 72 weeks at the highest dose. Early weight loss in the first 4-8 weeks on low doses is well-documented and often front-loaded with water weight and reduced caloric intake.

Losing 17 pounds in 6 weeks is on the higher end but not implausible, especially in the early weeks when appetite suppression is often sharpest even at 2.5 mg. A 2023 analysis in Obesity (Wilding et al.) confirmed that early response in weeks 1-4 can be disproportionately large relative to later weeks. Her decision to delay dose escalation because she's still losing is also clinically reasonable. The FDA titration schedule exists as a minimum, not a mandate.

The muscle loss concern she raised is legitimate. A 2024 study in Nature Medicine (Aronne et al.) found that GLP-1 and GIP receptor agonists like tirzepatide can result in lean mass loss alongside fat loss, particularly without resistance training. Adding the gym was a smart move.

What did they get wrong (or right)?

She got more right than wrong here. The titration logic is sound, the muscle concern is real, and she's transparent about dose and cost. But a few things are worth flagging.

Attributing her gastrointestinal episode entirely to "food poisoning" is worth scrutinizing. GI side effects, including nausea, vomiting, and diarrhea, are among the most common adverse events with tirzepatide, especially in early weeks. The SURMOUNT-1 trial reported nausea in up to 31% of participants and diarrhea in up to 23%. It may well have been food poisoning. But it also may not have been, and casually dismissing GI symptoms as something external could cause someone else to dismiss a real medication side effect.

She also says she "didn't really have any" side effects, which is fine for her experience, but at 116K views, that framing can set unrealistic expectations. Tirzepatide's GI side effect profile is significant, and the clinical trial data makes that clear.

Her goal of reaching 135 pounds would put her BMI at approximately 24.7, which is within the "normal" range. That's a reasonable, medically grounded target, even if she didn't frame it that way.

What should you actually know?

Tirzepatide works on both GIP and GLP-1 receptors, which is what separates Zepbound from semaglutide-based drugs like Wegovy. The dual mechanism appears to produce greater weight loss in head-to-head comparisons. A 2023 trial in JAMA Internal Medicine (Bhatt et al.) found tirzepatide outperformed semaglutide for weight reduction, though both carry similar GI side effect profiles.

The $277 price point she mentions likely reflects a manufacturer coupon or savings program. List price for Zepbound without insurance runs significantly higher. Anyone considering this medication should know that cost and access vary widely, and compounded tirzepatide, while cheaper in some markets, is not equivalent to the branded product and carries its own regulatory and safety considerations.

Staying on 2.5 mg longer than the standard four-week titration period is not inherently dangerous. But dose decisions should involve a prescribing clinician, not just personal comfort with the scale. Adding resistance training to preserve lean mass, as she did, is backed by evidence and worth doing regardless of what the number on the scale says.